BUTTERWORTH, SAM,WARD, RICHARD ANDREW,FINLAY, MAURICE RAYMOND VERSCHOYLE,KADAMBAR, VASANTHA KRISHNA,CHINTAKUNTLA, CHANDRASEKHARA REDDY,MURUGAN, ANDIAPPAN,CHUAQUI, CLAUDIO EDMUNDO,REDFEARN, HEATHER MAR
申请号：
PL17194307
公开号：
PL3333161T3
申请日:
2012.07.25
申请国别(地区):
PL
年份:
2020
代理人:
摘要：
The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.
